The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Sinden, Nicola J ^a   Koura, Firas ^b   Stockley, Robert A ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Kentucky Lung Clinic PSC Appalachian Regional Healthcare   (United States)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Alpha 1 antitrypsin deficiency; Emphysema; Proteinases; Serpin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; CARBIDOPA PLUS LEVODOPA; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCHLOROTHIAZIDE; LEUKOCYTE ELASTASE; METHYLAMINE; METOPROLOL; MONTELUKAST; MYELOBLASTIN; OMEPRAZOLE; ROFLUMILAST; ROSUVASTATIN; SALBUTAMOL;

ADULT; AGED; AIRWAY OBSTRUCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BODY MASS; BRADYCARDIA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COR PULMONALE; CORONARY ARTERY DISEASE; COUGHING; DYSPNEA; ECHOCARDIOGRAPHY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; HETEROZYGOTE; HOME OXYGEN THERAPY; HOMOZYGOTE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER DISEASE; MALE; NEPHROLITHIASIS; OXYGEN SATURATION; PHENOTYPE; PLEURA THICKENING; PROTEIN BLOOD LEVEL; RESTLESS LEGS SYNDROME; RISK FACTOR; ANTAGONISTS AND INHIBITORS; CASE REPORT; COMPLICATION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; KINETICS; METABOLISM;

AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; EMPHYSEMA; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; KINETICS; LEUKOCYTE ELASTASE; MALE; MYELOBLASTIN; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84905972955     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-132     Document Type: Article

References (27)

1. Eriksson S. Pulmonary Emphysema and Alpha1-Antitrypsin deficiency. Acta Med Scand 1964, 175:197-205.
2. Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest 1999, 104(3):337-344.
3. Fagerhol MK, Braend M. Serum prealbumin: polymorphism in man. Science 1965, 149(3687):986-987.
4. Okayama H, Brantly M, Holmes M, Crystal RG. Characterization of the molecular basis of the alpha 1-antitrypsin F allele. Am J Hum Genet 1991, 48(6):1154-1158.
5. Cook L, Burdon JG, Brenton S, Knight KR, Janus ED. Kinetic characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil elastase. Pathology 1996, 28(3):242-247.
6. Cockcroft DW, Tennent RK, Horne SL. Pulmonary emphysema associated with the FZ alpha 1-antitrypsin phenotype. Can Med Assoc J 1981, 124(6):737-742.
7. Beckman G, Stjernberg NL, Eklund A. Is the PiF allele of alpha 1-antitrypsin associated with pulmonary disease?. Clin Genet 1984, 25(6):491-495.
8. Kelly CP, Tyrrell DN, McDonald GS, Whitehouse DB, Prichard JS. Heterozygous FZ alpha 1 antitrypsin deficiency associated with severe emphysema and hepatic disease: case report and family study. Thorax 1989, 44(9):758-759.
9. Ringenbach MR, Banta E, Snyder MR, Craig TJ, Ishmael FT. A challenging diagnosis of alpha-1-antitrypsin deficiency: identification of a patient with a novel F/Null phenotype. Allergy Asthma Clin Immunol 2011, 7(1):18.
10. Nakajima K, Powers JC, Ashe BM, Zimmerman M. Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem 1979, 254(10):4027-4032.
11. Musumeci V, Vincenti A, Bizzi B. A method for the differential determination of plasma antithrombins. J Clin Pathol 1976, 29(1):63-68.
12. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987, 80(5):1366-1374.
13. Korkmaz B, Attucci S, Juliano MA, Kalupov T, Jourdan ML, Juliano L, Gauthier F. Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates. Nat Protoc 2008, 3(6):991-1000.
14. Billingsley GD, Cox DW. Functional assessment of genetic variants of alpha 1-antitrypsin. Hum Genet 1982, 61(2):118-122.
15. Brand B, Bezahler GH, Gould R. Cirrhosis and heterozygous FZ alpha1-antitrypsin deficiency in an adult. Case report and review of the literature. Gastroenterology 1974, 66(2):264-268.
16. Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 1991, 100(3):703-708.
17. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004, 59(10):843-849.
18. Seersholm N, Wilcke JT, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000, 161(1):81-84.
19. Sorheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, Agusti A, Calverley PM, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EF, Pare PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK. alpha(1)-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010, 138(5):1125-1132.
20. Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, Greene CM, O'Neill SJ, Silverman EK, McElvaney NG. Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014, 189(4):419-427.
21. Holme J, Stockley RA. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. Chest 2009, 136(5):1284-1290.
22. Lomas DA, Mahadeva R. Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 2002, 110(11):1585-1590.
23. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 1986, 314(12):736-739.
24. Mahadeva R, Chang WS, Dafforn TR, Oakley DJ, Foreman RC, Calvin J, Wight DG, Lomas DA. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest 1999, 103(7):999-1006.
25. Kim S, Woo J, Seo EJ, Yu M, Ryu S. A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin shows variability of the reactive center and other loops. J Mol Biol 2001, 306(1):109-119.
26. Korkmaz B, Poutrain P, Hazouard E, de Monte M, Attucci S, Gauthier FL. Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor. Am J Respir Cell Mol Biol 2005, 32(6):553-559.
27. Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with Alpha-1-Antitrypsin deficiency and COPD. Eur Respir J 2013, 41(5):1042-1050.